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Regulatory T cells (Treg) are a subset of T cells with strong immunosuppressive activity. 
In the skin, it has recently been revealed that Treg play important roles not only in the 
maintenance of skin homeostasis but also in the regulation of the immune responses, 
such as contact hypersensitivity and atopic dermatitis. Furthermore, the skin plays 
important roles in the induction of Treg in the periphery. In this review, we will provide 
an overview of the mechanism of Treg-mediated immunosuppression and discuss the 
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 T cells are essential for the maintenance of self-tolerance. 
Later on, the forkhead box p3 (Foxp3) gene was identified as the master transcriptional 
factor of Treg [3].  
There are at least two kinds of Foxp3
+
 Treg: naturally occurring Treg (nTreg) and 
inducible Treg (iTreg) [4]. nTreg develop in the thymus, and play an important role in 
the maintenance of self-tolerance and immune homeostasis. Scurfy mice, which possess 
a defective Foxp3 gene, exhibit hyperactivation of CD4
+
 T cells and overproduction of 
proinflammatory cytokines, and typically die within a month after birth [5]. Patients 
with IPEX syndrome (immune dysregulation polyendocrinopathy, enteropathy, 
X-linked syndrome) have a mutation in the human FOXP3 gene, and are therefore 
regarded as the human counterpart of scurfy mice [6]. iTreg, on the other hand, are 
induced from naïve T cells in the presence of transforming growth factor (TGF)-, and 
develop in the periphery. Retinoic acid facilitates the differentiation of naïve T cells to 
Foxp3
+
 Treg [7] [8] and may be related to the establishment of oral tolerance, although 
it remains to be determined whether iTreg are functionally stable and to what extent 
they contribute under physiological conditions.  
In addition to Foxp3
+
 Treg, there are other types of Treg, such as Tr1 and Th3 cells; 
these are induced in the periphery [4] [9] [10].  Tr1 cells can be induced through the 
antigenic stimulation of naïve T cells in the presence of IL-10 in vitro, and exert a 
suppressive effect in vitro by inducing large amounts of IL-10 and TGF-. Th3 cells 
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produce TGF- in an antigen-specific manner, and exert a suppressive effect. 
Intriguingly, however, both are Foxp3 and CD25 negative. No further details of this 
population are discussed in this manuscript. 
Evidence has accumulated regarding the regulatory roles of Treg not only in 
self-tolerance, but also in a variety of pathophysiological immune responses, such as 
gastritis [11], arthritis, encephalomyelitis [12], inflammatory bowel disease (IBD) [13], 
insulin-dependent diabetes [14] and various allergic skin diseases such as contact 
hypersensitivity or atopic dermatitis.  
  In this review, we will provide an overview of the mechanism of Treg-mediated 
immunosuppression, mainly focusing on Foxp3
+
 Treg, and discuss the role of Treg in 
the skin immune responses, focusing on contact hypersensitivity and atopic dermatitis. 
 
 
1. Mechanism of suppression by Treg  
Treg potently suppress the proliferation of T cells when Treg are co-cultured with 
responder cells that have been stimulated with a specific antigen or a polyclonal T cell 
receptor stimulator in vitro. Multiple suppression mechanisms have been proposed 
based on in vitro assays; for example, IL-10 [13], TGF-[15], and IL-35 [16]  have 
been considered as possible soluble suppressive factors of T cell proliferation. 
Absorption of IL-2 by Treg may also be involved in inhibiting T cell proliferation [17]. 
It has also been reported that Treg exert their regulatory functions by cell-cell 
contact-dependent factors, such as CD39/CD73 [18] and granzyme/perforin [19]. In 
addition to these direct suppressive effects, Treg indirectly suppress T cell proliferation 
by affecting the function of APCs. It has been reported that Treg inhibited the T cell 
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stimulatory capacity of APCs by down-regulating CD80 and CD86 expression through 
cytotoxic T-lymphocyte antigen (CTLA)-4 and lymphocyte function-associated antigen 
(LFA)-1 [20]. Using two-photon microscopic analysis, Tadokoro et al [21] and Tang et 
al [14]  have revealed that Treg inhibit stable contact and interaction between APCs 
and effector T cells. Treg also stimulate DCs to express the enzyme indoleamine 
2,3-dioxygenase (IDO), which catabolizes the conversion of tryptophan to kynurenine, a 
toxic factor to T cells [22]. In addition to their effect on APCs, it has also been reported 
that Treg down-regulate mast cell function by suppressing mast cell degranulation and 
anaphylactic response through OX40-OX40L interaction [23]. The mechanisms by 
which suppression is achieved may vary depending on context, however, and it has not 
yet been determined how these in vitro findings correlate with in vivo suppression. 
 
2. Characterization of Treg in the skin 
Treg exist in all non-lymphoid tissues; the skin has a particularly high proportion of 





[26], and express the chemokine receptors CCR4, CCR5, CCR6 and CCR7. CCR5
+
 
Treg preferentially migrate to cutaneous lesions of Leishmania major infection [27]. 
Mice with a complete loss of CCR4 on Treg develop spontaneous lymphocytic 
infiltration and severe inflammation in the skin and lungs, accompanied by peripheral 




 T cells. 
Using α-1,3-fucosyltransferase VII (Fut7) deficient mice, Dudda et al [26] have reported 
the importance of E- and P-selectin ligand for Treg migration to the skin. Loss of these 
selectin bindings caused skin-specific inflammation, indicating the essential role of 




3. Treg induction and expansion in the skin 
Ultraviolet (UV) radiation to the skin is well known to cause immunosuppression, and 
is accordingly applied as a treatment for a wide variety of skin diseases. Recently, it has 
been revealed that one of the immunosuppressive mechanisms involved in this effect is 
mediated by Treg, which are induced by UV irradiation [28]. It has been proposed that 
the cells responsible for this induction of Treg are epidermal Langerhans cells (LCs), an 
important group of skin-resident dendritic cells. Loser et al. [29] have reported that the 
receptor activator of NF-kappaB ligand (RANKL) was induced in keratinocytes by UV 
exposure, and RANKL-activated LCs were responsible for the development of 
UV-induced Treg. It has also been reported that the induction of Treg by UV irradiation 
was completely abolished by the depletion of LCs using Langerin-DTR mice or steroid 
mometasone [30] [31]. In addition, it has recently been reported that IL-10-producing 
and OX40 ligand-expressing mature LCs are responsible for the induction of Treg upon 
UV exposure [31], suggesting the importance of LCs for Treg induction. In addition to 
UV-induced immunosuppression, similar findings were observed concerning the 
mechanisms involved in immunosuppression during skin grafting. Yoshiki et al. [32] 
have reported that the development of contact hypersensitivity (CHS) was suppressed 









 T cells in draining lymph nodes (LNs) were 
responsible for this suppression. In addition, a high expression of RANKL was 
observed in the grafted skin, and recombinant RANKL stimulated LCs to produce IL-10. 
These findings suggest that the LCs play important roles in the peripheral induction of 
Treg. Recently, it has been reported that glucocorticoids modify LCs to produce TGF- 
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and expand regulatory T cells in humans [33], implying that glucocorticosteroids may 
exert their anti-inflammatory functions by inducing Treg.  
  The phenotypes and suppression mechanisms of UV-induced Treg are different from 





 cells from UV-irradiated DNFB-sensitized mice impaired sensitization of 
CHS. These UV-induced Treg did not suppress the CHS response when administered 




 Treg did. Direct injection of UV-induced 
Treg into the elicitation sites did suppress the CHS response, however. They 
accordingly concluded that UV-induced Treg did not express skin-homing receptors for 
E- and P-selectins, and so failed to suppress elicitation. In addition, they reported that 
UV-induced Treg changed APCs in LNs from a stimulatory to a regulatory phenotype 
by modulating the co-stimulatory molecules on APCs, which, in turn, further induce 
Treg [36].  
  Although the importance of LCs has been suggested as mentioned above, other 
groups have reported the importance of dermal DCs in UV-induced immunosuppression 
and peripheral Treg induction. Wang et al. [37] reported the UV-induced 
immunosuppression was abolished by selective depletion of Langerin-positive dermal 
DCs, suggesting the importance of Langerin-positive dermal DCs in Treg induction. It 
has also been reported that retinoic-acid producing CD103-negative dermal dendritic 
cells have the ability to induce Treg in draining LNs [38], in contrast to the equivalent 





4.  Treg in CHS 
CHS, a frequently used mouse model of contact dermatitis, is a prototype of skin 
immune response, and the role of Treg in CHS has been gradually revealed. 
   The development of CHS is divided into two phases: sensitization and elicitation 
[40]. In the sensitization phase, low molecular weight compounds called haptens are 
cross-linked to epidermal proteins and taken up by resident DCs such as LCs and 
dermal DCs. Subsequently, these cells are matured by proinflammatory cytokines such 
as TNF-α, IL-1β, and prostaglandin E2, and migrate to the draining LNs to present 
antigens in a CCR7 and CXCR4-dependent manner [41, 42]. After antigen 
presentation, naive T cells are activated and differentiated into antigen-specific Th1 
and Tc1 cells under the influence of polarizing signals such as IL-12 and other 
chemical mediators [43]. Th17 cells are also involved in the pathogenesis of CHS [44]. 
When the skin is re-exposed to the same hapten after establishment of the sensitization, 
an antigen-specific T cell-mediated inflammation that is known as elicitation phase is 
provoked. Upon re-exposure to the same hapten, keratinocytes and mast cells produce 
chemokines and pro-inflammatory cytokines such as TNF-α and IL-1β, which activate 
endothelial cells and induce the expression of E- or P-selectins [45-47]. Then, 
neutrophils and antigen-specific T cells enter the dermis and release IFN-, which 
further stimulates keratinocytes to induce massive leukocyte infiltration [48]. 
 
 a. Treg in the CHS response - elicitation phase 
The effect of Treg on CHS has mainly been investigated in the elicitation phase. Ring et 




 Treg from naïve mice and administered them into 
TNCB-sensitized recipient mice intravenously one day before elicitation [49]. 
10 
 
Administration of Treg significantly suppressed the ear swelling response and 
inflammatory cell infiltration into the skin compared to those of vehicle-treated mice.  
Ring et al. have reported that these suppressive effects are mediated by soluble factors, 
especially IL-10. Administration of a culture supernatant of Treg suppressed the CHS 
response, and this suppression was reversed by an anti-IL-10 Ab. Furthermore, Treg 
from IL-10-deficient mice failed to suppress the CHS response by inhibiting the 
leukocyte influx into the inflamed skin.  
   The same group has recently reported that the adenosine produced by Treg is 
involved in blocking the influx of leukocytes into the skin by downregulating E- and P- 
selectins on endothelial cells [50]. Adenosine triphosphate (ATP) is first degraded by 
CD39 to adenosine diphosphate (ADP) and then to adenosine monophosphate (AMP). 
The AMP is serially dephosphorylated by CD73 to adenosine. Treg are strongly positive 
for both CD39 and CD73 expression; therefore, Treg convert ATP to adenosine and 
suppress the CHS response. On the other hand, conventional T cells exhibit only a low 
basal expression level of CD39. Accordingly, injection of adenosine or Treg abrogated 
the ear-swelling response in CHS, which was not seen using Treg from CD39-deficient 
mice [50]. Moreover, Treg further upregulate CD39 expression after activation; this 
activation is a prerequisite for Treg to acquire their suppressive capacity.   
b. Treg in the CHS response - sensitization phase 
While reports on the role of Treg in the sensitization phase have been rather limited 
compared to those discussing the elicitation phase, some interesting reports have 
recently been published. Dubois et al. [51], for example, have reported the involvement 
of Treg in the induction of oral tolerance and inhibition of DNFB-induced CHS. Oral 
tolerance was induced by feeding DNFB orally prior to DNFB sensitization. Although 
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no such tolerance induction was seen in CD4
+





 T cells restores oral tolerance in those mice, in a manner independent of 
IL-10 [51]. The same authors also showed that administration of neutralizing anti-CD25 
monoclonal antibody (mAb) impairs oral tolerance in WT mice. Intriguingly, 
administration of anti-CD25 mAb before sensitization had no significant affect on the 




 T cells are responsible for oral 
tolerance induction, while the role of Treg in the sensitization phase remained unclear. 
Ring et al. have recently reported that the administration of Treg suppressed the extent 
of sensitization in CHS by inhibiting DCs and CD8 T cells in the draining LNs [52]. In 
their report, Treg and DCs established a gap junctions, which caused a reduction in the 
capacity of DCs to stimulate CD8 T cells. In their next report, the same authors stated 
that Treg activation in draining LNs was mediated by ATP, because Treg acquired an 
activated phenotype upon ATP treatment in vitro, while blockage of ATP receptors on 
Treg abrogated ATP-mediated activation and suppressive function of Treg in vivo [53]. 
 
c. The role of endogenous Treg in CHS 
As described above, exogenous administration of Treg suppresses CHS both in the 
sensitization phase and in the elicitation phase. It remains unclear, however, whether 
endogenous Treg play the same suppressive role under physiological conditions. To this 




 has been used 
as a marker for Treg, CD25 is expressed in activated CD4 cells as well as in Treg. 
Therefore, Foxp3 is a more definitive marker of Treg, but because Foxp3 is a 
transcriptional factor that exists intracellularly, the purification of live Treg or depletion 
by means of neutralizing mAb has been technically difficult. 
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   To solve these problems, Foxp3 reporter mice expressing human CD2 and human 





 cells co-express hCD2 on the cellular surface, live Foxp3
+
 Treg are sorted 
with anti-hCD2 mAb and depleted with neutralizing anti-hCD52 Ab [25]. The mice 
have been used in the investgations into the role of endogenous Treg in CHS. Depletion 
of Treg in the elicitation phase caused the ear swelling response to be enhanced and 
prolonged compared with that seen in the control, indicating that Treg is responsible for 
terminating skin inflammation in CHS [25].  
   In addition, the role and mobility of Treg in the skin during CHS was investigated. 
Kaede-transgenic mice are genetically engineered to ubiquitously express Kaede protein, 
a photoconvertible protein that changes its fluorescence from green to red under 
exposure to violet light. Therefore, mobility of cells from the skin under physiological 
conditions can be analyzed. Treg were found to localize abundantly in the inflamed skin 
seen in CHS, and these skin Treg were found to migrate further back to draining LNs. 
Treg from the skin showed significantly higher mRNA expression of T cell 
suppression-associated molecules such as IL-10, TGF- and CTLA4. Consistently, Treg 
from the skin exhibited significantly stronger suppressive activity both in vivo and in 
vitro (Figure 1). These results suggest that Treg in the skin also play important roles in 
the termination of dermatitis and possibly in the control of systemic immune responses.  
   It has been suggested that Treg in the skin contribute to its homeostasis, since 
chronic depletion of skin Treg leads to the development of spontaneous dermatitis [24] 
[26]. Schneider et al. have reported that CCR7-deficient mice showed a reduced number 
of Treg in draining LNs and an enhanced inflammatory response in CHS after repeated 
hapten application [54], which suggests the homing of Treg to draining LNs through 
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CCR7 plays an important role in eliciting the function of Treg.  
   Endogenous Treg regulate the extent of sensitization as well as that of challenge in 
CHS. Depletion of Treg during the sensitization phase leads to enhanced skin 
inflammation [55]. Mice depleted with Treg population showed increased numbers of 
memory T cells and higher expression levels of costimulatory molecules in DCs in 
draining LNs compared with control mice, suggesting that endogenous Treg modulate 
DC function and thus regulate the extent of sensitization [55]. Recent findings on the 
role of Treg in CHS are summarized in Table 1, and schematic views of those findings 
are illustrated in Figures 3 and 4 
 
5. Atopic dermatitis (AD) and Treg 
Atopic dermatitis is one of the most common skin inflammatory disorders. New insights 
point to an important role of structural abnormalities in the epidermis combined with 
immune dysregulation [56]. Although studies on the role of Th2 cells have focused on 
the pathophysiology of AD, recent reports have indicated the importance of other T cell 
subsets such as Th17 [57] and Treg.  
   Ou et al. [58] have compared the numbers and functionality of peripheral blood 
mononuclear cells (PBMC) between healthy controls and AD patients, and reported that 
AD patients have higher numbers of Treg, each with a suppressive activity comparable 
to that of Treg in healthy controls, in the peripheral blood. Others have also reported 
that increased numbers of Treg in the PBMC of AD patients [59] and expansion of Treg 
were positively associated with disease activity in AD [60]. On the other hand, it has 
also been reported that the numbers of Treg among the PBMC are similar between AD 
and healthy controls [61]. In AD skin lesions, it was initially reported that Treg were 
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absent, while Tr1 were detected [62]. Later on, however, several groups reported the 
existence of Treg in AD skin lesions [63, 64]. Because AD is a chronic inflammatory 
disease with multiple disease stages and multiple factors, and because some treatments 
for AD such as cyclosporine [59, 61, 65], glucocoriticoids [33] and UV radiation [28], 
can alter the number of Treg in the PBMC, the interpretation and comparison of these 
studies will require careful attention.  
   Based on observations of IPEX syndrome patients, who show atopic-like dermatitis 
and high IgE levels, however, it seems probable that the number of Treg is related to the 
development of AD lesions [6]. As for the function of Treg in AD, it has been reported 
that their suppressive activity is similar to that of Treg in healthy controls [58]. Reefer 
et al., however, have reported that a new subtype of Treg with Th2-promoting ability 
has been observed in AD and that its functions depend on the expression of CCR6 [66]. 
In this report, CCR6-negative CD25-high positive Treg produced Th2 cytokines, and 
co-culture with effector T cells selectively enhanced IL-5 production, suggesting the 
heterogeneity of Treg in AD.   
Recently, dysfunction of Treg has been reported in psoriasis [67], another chronic 
inflammatory skin disease. Treg in both lesional skin and blood from psoriasis patients 
showed reduced suppressive activity [67], and such dysfunction was dependent on the 
signaling from IL-6, which was abundantly produced in psoriasis lesion [68]. Local 




We have reviewed the roles of Treg in cutaneous immune responses. A considerable 
15 
 
amount of knowledge on Treg has been accumulated, and multiple mechanisms and 
various molecules are reported to be involved in Treg-mediated immunosuppression. It 
is likely that the suppressive mechanisms of Treg may differ depending on disease stage 
and the skin immune response type. Analysis using Foxp3-diphtheria toxin receptor 
knockin mice or Foxp3
hCD2/hCD52
 mice, which enable us to deplete Treg conditionally 
and specifically, will further reveal the molecular mechanisms and physiological 
functions of Treg in cutaneous immune responses.  
   It is crucially important to clarify how and to what extent those molecules are 
involved in Treg function in humans. From a clinical perspective, the precise 
mechanism by which Treg function in the elicitation phase is an important issue to be 
addressed, since most patients with cutaneous immune disease have already been 
sensitized. We expect that further effort in the investigation of Treg will give us 
important clues supporting the development of innovative therapeutic approaches for 
various skin diseases. 
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Figure1. Possible mechanisms involved in suppression by Treg 
(a) Soluble factor-dependent mechanisms. Treg produce large amounts of IL-10, IL-35, 
and TGF-beta, all of which suppress naive/effector T cell activation. Treg also absorb 
IL-2, which causes cytokine deprivation-induced apoptosis among effector T cells. (b) 
Contact-dependent mechanisms. CTLA-4 on Treg deliver negative signals to T cells. 
CD39/CD73 on Treg catalyze ATP and generate pericellular adenosine, exerting an 
anti-inflammatory effect. Treg also may kill responder T cells by a granzyme or 
perforin-dependent mechanisms. (c) Indirect mechanisms. Treg inhibit the interaction 
between DCs and effector T cells. Treg also downregulate DC activation and thus cause 
immunosuppression. 
 
Figure 2. Proposed mechanism of Treg induction by skin DCs  
UV exposure or skin grafting induces RANKL expression on keratinocytes, which 
stimulate LCs. RANKL-stimulated LCs then induce Treg in draining LNs. Under 
conditions of UV exposure, it has also been proposed that the UV-induced Treg affect 
DCs and modify their functions from a stimulatory phenotype to a regulatory phenotype, 
which further induces Treg. In addition to LCs, CD103-negative dermal DCs can induce 
Treg in draining LNs. 
 
Figure 3. Possible mechanism of suppression by Treg in sensitization phase of CHS 
Treg are activated in draining LNs by ATP. They down-regulate DC activation through 





Figure 4. Possible mechanism of suppression by Treg in elicitation phase of CHS 
Treg suppress effector T cells in the LNs and inhibit leukocyte influx into the periphery 
through IL-10 or CD39-dependent mechanisms. In addition, Treg migrating into the 
skin could suppress the effector T cell functions in the skin. Furthermore, a fraction of 
Treg in the skin migrate back to the draining LNs through afferent lymphatic vessels, 
and can return from there to the skin. These skin-derived Treg possess higher 









Table 1.  An overview of recently published papers about Treg and CHS 
 
 Major findings Reference 
 Attenuated sensitization by Treg induced by RANKL-activated LC 
in a UV-immunosuppression model 
[29] 
Sensitization Attenuated sensitization by Treg induced by IL-10 from 
RANKL-activated LC in a skin graft immunosuppression model 
[32] 
 Attenuated sensitization by Treg induced by orally administered 
antigen in an oral tolerance model 
[51] 
 
 Treg attenuate sensitization by modifying DC function through gap 
junction formation 
[52] 
 Treg acquire an activated phenotype by means of ATP in draining 
LNs 
[53] 
 Enhanced ear swelling response resulting from the depletion of 
endogenous Treg 
[55] 
 Reduced ear swelling response resulting from the inhibition of the 
leukocyte influx through IL-10 from Treg  
[49] 
Elicitation Reduced ear swelling response resulting from the inhibition of the 
leukocyte influx through adenosine from Treg via CD39/CD73  
(inhibition of E- and P-selectin expression in endothelial cells) 
[50] 
 Treg acquire activated phenotype by means of ATP in blood. [53] 
 Enhanced and prolonged ear swelling response resulting from 
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